Compare BIO & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | WH |
|---|---|---|
| Founded | 1952 | 2017 |
| Country | United States | United States |
| Employees | 7450 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Hotels/Resorts |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.4B |
| IPO Year | N/A | 2017 |
| Metric | BIO | WH |
|---|---|---|
| Price | $287.98 | $79.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $339.75 | $94.10 |
| AVG Volume (30 Days) | 430.6K | ★ 1.0M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.80 |
| Revenue | N/A | ★ $1,429,000,000.00 |
| Revenue This Year | $2.74 | $6.86 |
| Revenue Next Year | $3.20 | $5.83 |
| P/E Ratio | ★ $9.72 | $100.81 |
| Revenue Growth | N/A | ★ 1.49 |
| 52 Week Low | $211.43 | $69.21 |
| 52 Week High | $343.12 | $92.69 |
| Indicator | BIO | WH |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 42.47 |
| Support Level | $259.31 | $70.82 |
| Resistance Level | $288.48 | $82.13 |
| Average True Range (ATR) | 8.98 | 2.59 |
| MACD | 4.66 | -0.28 |
| Stochastic Oscillator | 93.29 | 27.62 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
As of Dec. 31, 2025, Wyndham Hotels & Resorts operates 869,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Ramada is the largest brand, representing around 14% of all rooms, with Days Inn (13%) and Super 8 (10%) the next two largest brands, as of the end of 2025. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represented 58% of total rooms in 2025.